Chemotherapeutic palliative approaches in the treatment of lymphoma

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

A number of diverse therapies can be used to treat relapsed non-Hodgkin's lymphoma, with the most common treatment modality being conventional salvage chemotherapy using agents different from those used initially. Alternative therapies that may be palliative in certain clinical situations include localized radiation therapy, novel chemotherapeutic agents (like chlorodeoxyadenosine, fludarabine, or idarubicin), or conjugated monoclonal antibody therapy. The use of high-dose chemotherapy and bone marrow or hematopoietic stem cell transplantation can be a successful treatment option for patients with relapsed lymphoma; however, this should be considered as a therapy of curative intent and not only for palliative therapy.

Original languageEnglish (US)
Pages (from-to)53-57
Number of pages5
JournalSeminars in Oncology
Volume22
Issue numberSUPPL. 3
StatePublished - Jan 1 1995

Fingerprint

Lymphoma
Idarubicin
Therapeutics
Drug Therapy
Hematopoietic Stem Cell Transplantation
Complementary Therapies
Palliative Care
Non-Hodgkin's Lymphoma
Radiotherapy
Bone Marrow
Monoclonal Antibodies

ASJC Scopus subject areas

  • Oncology

Cite this

Chemotherapeutic palliative approaches in the treatment of lymphoma. / Vose, Julie Marie.

In: Seminars in Oncology, Vol. 22, No. SUPPL. 3, 01.01.1995, p. 53-57.

Research output: Contribution to journalArticle

@article{a31839710d0e466794e3dd1096e2a969,
title = "Chemotherapeutic palliative approaches in the treatment of lymphoma",
abstract = "A number of diverse therapies can be used to treat relapsed non-Hodgkin's lymphoma, with the most common treatment modality being conventional salvage chemotherapy using agents different from those used initially. Alternative therapies that may be palliative in certain clinical situations include localized radiation therapy, novel chemotherapeutic agents (like chlorodeoxyadenosine, fludarabine, or idarubicin), or conjugated monoclonal antibody therapy. The use of high-dose chemotherapy and bone marrow or hematopoietic stem cell transplantation can be a successful treatment option for patients with relapsed lymphoma; however, this should be considered as a therapy of curative intent and not only for palliative therapy.",
author = "Vose, {Julie Marie}",
year = "1995",
month = "1",
day = "1",
language = "English (US)",
volume = "22",
pages = "53--57",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Chemotherapeutic palliative approaches in the treatment of lymphoma

AU - Vose, Julie Marie

PY - 1995/1/1

Y1 - 1995/1/1

N2 - A number of diverse therapies can be used to treat relapsed non-Hodgkin's lymphoma, with the most common treatment modality being conventional salvage chemotherapy using agents different from those used initially. Alternative therapies that may be palliative in certain clinical situations include localized radiation therapy, novel chemotherapeutic agents (like chlorodeoxyadenosine, fludarabine, or idarubicin), or conjugated monoclonal antibody therapy. The use of high-dose chemotherapy and bone marrow or hematopoietic stem cell transplantation can be a successful treatment option for patients with relapsed lymphoma; however, this should be considered as a therapy of curative intent and not only for palliative therapy.

AB - A number of diverse therapies can be used to treat relapsed non-Hodgkin's lymphoma, with the most common treatment modality being conventional salvage chemotherapy using agents different from those used initially. Alternative therapies that may be palliative in certain clinical situations include localized radiation therapy, novel chemotherapeutic agents (like chlorodeoxyadenosine, fludarabine, or idarubicin), or conjugated monoclonal antibody therapy. The use of high-dose chemotherapy and bone marrow or hematopoietic stem cell transplantation can be a successful treatment option for patients with relapsed lymphoma; however, this should be considered as a therapy of curative intent and not only for palliative therapy.

UR - http://www.scopus.com/inward/record.url?scp=0028919751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028919751&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 53

EP - 57

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - SUPPL. 3

ER -